FORMYCON AG |
Market Closed -
Other stock markets
|
After market 18:35:08 | |||
| 41 EUR | +0.12% |
|
41.2 | +0.49% |
| 04-25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 89% by 2026.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -27.39% | 772M | - | ||
| +0.67% | 42.4B | B | ||
| +44.30% | 40.04B | A | ||
| -6.20% | 28.31B | C | ||
| +6.55% | 24.94B | B- | ||
| -21.66% | 18.96B | B | ||
| +29.96% | 12.3B | C+ | ||
| -1.57% | 11.95B | C+ | ||
| +16.03% | 11.32B | B+ | ||
| -4.80% | 11.55B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- FYB Stock
- Ratings Formycon AG
